Attenuated negative strand viruses with altered interferon...

Details Attenuated negative strand viruses with altered interferon... Attenuated negative strand viruses with altered interferon...

2008-04-22

2011-11-15

Blumel, Benjamin P (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S209100

Reexamination Certificate

active

08057803

ABSTRACT:
The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses.In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.

REFERENCES:
patent: 4071618 (1978-01-01), Konobe et al.
patent: 4567147 (1986-01-01), Ooi et al.
patent: 4659569 (1987-04-01), Mitsuhashi et al.
patent: 5166057 (1992-11-01), Palese et al.
patent: 5674502 (1997-10-01), Ennis et al.
patent: 5766601 (1998-06-01), Palese et al.
patent: 5786199 (1998-07-01), Palese et al.
patent: 5820871 (1998-10-01), Palese et al.
patent: 5854037 (1998-12-01), Palese et al.
patent: 5866694 (1999-02-01), Katinger et al.
patent: 5882650 (1999-03-01), Ennis
patent: 6146642 (2000-11-01), Garcia-Sastre et al.
patent: 6146873 (2000-11-01), Kistner et al.
patent: 6300090 (2001-10-01), Steinman et al.
patent: 6326151 (2001-12-01), Katze et al.
patent: 6468544 (2002-10-01), Egorov et al.
patent: 6544785 (2003-04-01), Palese et al.
patent: 6573079 (2003-06-01), Palese et al.
patent: 6635416 (2003-10-01), Palese et al.
patent: 6669943 (2003-12-01), Palese et al.
patent: 6673591 (2004-01-01), Lau
patent: 6686190 (2004-02-01), Lau
patent: 6800288 (2004-10-01), Ferko et al.
patent: 6852522 (2005-02-01), Palese et al.
patent: 6866853 (2005-03-01), Egorov et al.
patent: 6884414 (2005-04-01), Palese et al.
patent: 7060430 (2006-06-01), Palese et al.
patent: 7132271 (2006-11-01), Lau
patent: 7344722 (2008-03-01), Maassab et al.
patent: 7442527 (2008-10-01), Palese et al.
patent: 7494659 (2009-02-01), Katinger et al.
patent: 7494808 (2009-02-01), Palese et al.
patent: 7588768 (2009-09-01), Palese et al.
patent: 7833774 (2010-11-01), Palese et al.
patent: 2004/0109877 (2004-06-01), Palese et al.
patent: 2004/0253273 (2004-12-01), Palese et al.
patent: 2005/0054074 (2005-03-01), Palese et al.
patent: 2006/0216701 (2006-09-01), Palese et al.
patent: 2007/0122430 (2007-05-01), Shneider et al.
patent: 2007/0172929 (2007-07-01), Maassab et al.
patent: 2008/0050402 (2008-02-01), Zhou et al.
patent: 2008/0234175 (2008-09-01), Montelione et al.
patent: 2008/0254060 (2008-10-01), Palese et al.
patent: 2009/0010962 (2009-01-01), Palese et al.
patent: 2009/0028901 (2009-01-01), Palese et al.
patent: 2009/0123495 (2009-05-01), Sachet et al.
patent: 2009/0203114 (2009-08-01), Palese et al.
patent: 2010/0080827 (2010-04-01), Palese et al.
patent: 2010/0158942 (2010-06-01), Palese et al.
patent: 2010/0233785 (2010-09-01), Brandt et al.
patent: 100 20 505 (2001-10-01), None
patent: 0 702 085 (1996-03-01), None
patent: 0 780 475 (1997-06-01), None
patent: 0 780 475 (1997-06-01), None
patent: 1 085 904 (1999-12-01), None
patent: 1 086 207 (2007-01-01), None
patent: 1 773 384 (2007-04-01), None
patent: 1 855 713 (2007-11-01), None
patent: 1 098 961 (2008-01-01), None
patent: 1 962 893 (2008-09-01), None
patent: 59-39831 (1984-03-01), None
patent: WO 96/10632 (1996-04-01), None
patent: WO 96/34625 (1996-11-01), None
patent: WO 97/06270 (1997-02-01), None
patent: WO 97/08292 (1997-03-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 98/02530 (1998-01-01), None
patent: WO 98/13501 (1998-04-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 99/02657 (1999-01-01), None
patent: WO 99/15672 (1999-04-01), None
patent: WO 99/64068 (1999-12-01), None
patent: WO 99/64570 (1999-12-01), None
patent: WO 99/64571 (1999-12-01), None
patent: WO 01/64860 (2001-09-01), None
patent: WO 01/77394 (2001-10-01), None
patent: WO 02/24876 (2002-03-01), None
patent: WO 2006/083286 (2006-08-01), None
patent: WO 2006/088481 (2006-08-01), None
patent: WO 2007/064802 (2007-06-01), None
Aoki et al., 1996, “Differential sensitivity of two related viruses, Newcastle disease virus and Sendai virus, to interferon in mouse Had-2 cells selective inhibition of translation of NDV mRNA.” Arch Virol., 141(10):1847-62.
Arvin et al., 2006, “New viral vaccines”, Virology 344:240-9.
Baez et al., 1980, “Complete nucleotide sequence of the influenza A/PR/8/34 virus NS gene and comparison with the NS genes of the A/Udorn/72 and A/FPV/Rostock/34 strains”, Nucleic Acids Res. 8(23):5845-58.
Beatrice et al., 1980, “Immunogenicity in mice of temperature-sensitive mutants of vesicular stomatitis virus: early appearance in bronchial secretions of an interferon-like inhibitor”, J Gen Virol. 47:529-33.
Belardelli, 1996, “The neglected role of type I interferon in the T-cell response: implications for its clinical use”, Immunol. Today 17(8):369-72.
Briscoe et al., 1996, “Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state”, EMBO J. 15:799-809.
Buonagurio et al., 1986, “Evolution of human influenza A viruses over 50 years: rapid, uniform rate of change in NS gene”, Science. 232(4753):980-2.
Butterfield et al., 1978, “Vaccination for fowl plague”, Am J Vet Res. 39(4):671-4.
Chang et al., 1992, “The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase”, Proc. Natl. Acad. Sci USA 89:4825-4829.
Chen et al., 1999, “Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3′-end processing machinery”, EMBO J. 18(8):2273-83.
Constantinescu et al., 1995, “Expression and signaling specificity of the IFNAR chain of the type I interferon receptor complex”, Proc. Natl. Acad. Sci. USA 92:10487-91.
Cossins et al., 1993, “Precise Prediction of a Kk-Restricted Cytotoxic T Cell Epitope in the NS1 Protein of Influenza Virus Using an MHC Allele-Specific Motif”, Virology 193(1):289-95.
Crowe, 1998, “Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines”, Vaccine 16(14/15):1423-32.
Cruse et al., Eds. 2003, “Knockout Gene” in Illustrated Dictionary of Immunology, 2nd Edition, CRC Press p. 367.
De La Luna et al., 1995, “Influenza virus NS1 protein enhances the rate of translation initiation of viral mRNAs”, J Virol 69(4):2427-33.
Da Silva et al., 2006, “Vaccines under development; group B streptococcus, herpes-zoster, HIV, malaria and dengue”, Jornal de Pediatria 82 (Suppl 3):115-24.
Desmyter et al., 1968, “Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero)”, J Virol. 2(10):955-61.
Diaz et al., 1988, “Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines”, Proc Natl Acad Sci U S A. 85(14):5259-63.
Dulbecco et al., Eds. 1988, “Multiplication and Genetics of Animal Viruses.”, Virology Ch. 48 pp. 77-9.
Durbin et al., 1996, “Targeted disruption of the mouse Stat 1 gene results in compromised innate immunity to viral disease”, Cell. 84(3):443-50.
Efferson et al., 2006, “Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells.”, J Virol. 80(1):383-94.
Egorov et al., 1994, “[The NS gene—a possible determinant of apathogenicity of a cold-adapted donor of attenuation A /Leningrad/134/47/57 and its reassortants]”, Vopr Virusol. 39(5):201-5. Russian.
Egorov et al., 1998, “Transfectant influenza A viruses with long deletions in the NS1 protein grow efficient

Affiliated with

Also associated with

Rating

Attenuated negative strand viruses with altered interferon... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Attenuated negative strand viruses with altered interferon..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated negative strand viruses with altered interferon... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4311243